Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.

@article{Schafer2003EnhancementOC,
  title={Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.},
  author={Peter H. Schafer and Anita K. Gandhi and Michelle A Loveland and Roger S. Chen and H X Man and Paul P M Schnetkamp and Gregor Wolbring and Sowmya Govinda and Laura G. Corral and Faribourz Payvandi and George W. Muller and David I. Stirling},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2003},
  volume={305 3},
  pages={1222-32}
}
CC-4047 (Actimid) and CC-5013 (Revimid) belong to a class of thalidomide analogs collectively known as the immunomodulatory drugs (IMiDs), which are currently being assessed in the treatment of patients with multiple myeloma and other cancers. IMiDs potently enhance T cell and natural killer cell responses and inhibit tumor necrosis factor-alpha, interleukin (IL)-1 beta, and IL-12 production from LPS-stimulated peripheral blood mononuclear cells. However, the molecular mechanism of action for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…